One such strategy involves coupling the catalytic domain of PCSK9 with self-assembling ferritin nanoparticles, which induces an immune response and the production of antibodies against PCSK9, leading to a reduction in lipids and the inhibition of atherosclerosis in various mouse models [52,53]. Here, PCSK9 is linked to atherosclerosis.